Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
50 participants
OBSERVATIONAL
2023-05-09
2024-07-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Continuous Glucose Monitoring in Hospitalized Patients With Diabetes Mellitus
NCT04653454
Accuracy Comparison of Two CGMs in Hospitalized Patients
NCT05081817
Standardized Procedure for the Assessment of New-to-market Continuous Glucose Monitoring Systems
NCT01751932
A Study of the Continuous Glucose Monitoring System for Home Use in Patients With Diabetes
NCT04964752
Pilot Prospective CGM Quality Improvement (QI) Project in Pregnancy
NCT02556554
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study seeks to define the accuracy of POC fingerstick testing and CGM as compared to blood serum glucose monitoring via phlebotomy. It also seeks to better understand the frequency of hypo- and hyperglycemia in this population using continuous glucose monitoring during the first 10 days of admission. Ideally, an accurate method of monitoring glucose values in this population beside phlebotomy draws needs to be established.
Blood will be drawn shortly after participants admission to the unit as part of usual care and will continue to be drawn daily as usual care for the next 5 days. Patient blood sugar will be checked daily using POC finger sticks until hypoglycemia resolves. If patient choose to participate in this study, the investigators will do additional POC testing on days 6 and 8 POC finger sticks will be done 30-minutes post breakfast/lunch/dinner. On the same day the patient agrees to be in this study, the patient will have a Dexcom CGM placed to the back of their arm, or on another area of the body depending on the recommendation from the manufacturer (DEXCOM). Patient will wear the CGM for the full 10 days that the study is being conducted.
Patient will also be asked to complete a simple log regarding the date and time the patient received post Breakfast/lunch/dinner POC tests on days 6 and 8. The patient may ask the PSCA Patient Safety Care Attendant (PSCA) to assist patient with this task.
Data received from the Dexcom device will automatically be uploaded to the Dexcom cloud. Only the research statistician will have access to these data. Staff from Dexcom do not have access to these data.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CGM
Continuous Glucose Monitor
Patients will wear a CGM device on their arm for 10 days, while receiving standard of care blood draws and finger stick sugar checks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Continuous Glucose Monitor
Patients will wear a CGM device on their arm for 10 days, while receiving standard of care blood draws and finger stick sugar checks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Admission %IBW ≤ 75%
Exclusion Criteria
* %IBW \> 75% on admission
* Inability to give informed consent to participate/lacks decisional capacity
* Unable to follow the study protocol
* Transferred to the unit on a mental health hold/short term certification
* Treatment team refusal of patient's participation
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Denver Health and Hospital Authority
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kristin Sterrett
Kristin Sterrett, Hospitalist, Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kristin Sterrett, MD
Role: PRINCIPAL_INVESTIGATOR
Denver Health and Hospital Authority
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Denver Health and Hospital Authority
Denver, Colorado, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DenverHealth
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.